|
|
|
|
|
by nextos
2 days ago
|
|
I would say that lots of interesting things are happening in biotech, and these things are slowly building critical mass, similar to what happened in computer hardware during the period 1970-2000. Genomic platforms are now able to capture multiple measurements (e.g. RNA and chromatin openness) from single cells in large tissue slices/massive perturbation experiments. Once time gets baked into the equation, we will be able to build better models of systems biology. However, human trials will still be a major bottleneck. |
|